dsm-firmenich announces sale of yeast extracts business to Lesaffre

dsm-firmenich announces sale of yeast extracts business to Lesaffre

On June 12, 2024, dsm-firmenich announced the sale of its yeast extracts business to Lesaffre, a major global player in fermentation and microorganisms, headquartered in France.

Upon completion of the deal, dsm-firmenich will continue to supply yeast extracts produced in Delft to Lesaffre until the end of 2025, at which time yeast extract production in Delft will cease and the plant will be closed. As part of the deal, some of the dsm-firmenich employees engaged in the yeast extracts business will be employed by Lesaffre.

As part of the deal, the two companies will establish a technological partnership to continue the development of yeast extracts. A number of dsm-firmenich employees working in R&D in Delft will be working on this.

dsm-firmenich stresses that the decision to refocus its strategic activities does not change its commitment to the Delft location. For the company, the Biotech Campus Delft is a strategic location where today's technology builds on a proud history and will continue to be important for the future growth.

Delft is dsm-firmenich's largest location in the Netherlands with more than 1,000 employees working in science & research and food applications, and is home to the global headquarters of the Taste, Texture & Health business unit (revenue € 3 billion) - for which a new state-of-the-art office is currently being built on campus.

Read the full press release of dsm-firmenich here.